AGIO

Ivosidenib (ClarIDHy)

Advanced Cholangiocarcinoma

sNDA Submission

Exp Date

Q1 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Advanced Cholangiocarcinoma for ClarIDHy sNDA Submission

  • Clinical Trial (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

WHAT IS THE NEXT CATALYST EVENT?

  • sNDA submission


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q1 2020 


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION 

  • Cancer cells undergo metabolic reprogramming to gain survival advantages as they progress into malignant tumors. Genetic mutations of isocitrate dehydrogenase (IDH), a metabolic enzyme in the tricarboxylic-acid cycle, is one pathway by which some tissues may become cancerous. IDH1 and IDH2 mutant enzymes are found in a number of tumor types, including acute myelogenous leukemia (AML), glioma, chondrosarcoma and cholangiocarcinoma.

  • Even though the genetic correlation of mutated IDH enzymes to these tumor subtypes was very strong, exactly how mutant IDH could reprogram cellular metabolism to drive cancer formation was a mystery. This lack of understanding of IDH cancer biology represented a major scientific stumbling block in the effort to develop drugs to treat these diseases.

  • The breakthrough made by Agios scientists was the discovery that mutant IDH1 (and similarly IDH2) acquires a new activity to produce an oncometabolite called 2-hydroxyglutarate (2HG) at exceedingly high levels inside these tumor cells. Subsequent investigative work in collaboration with several renowned academic researchers revealed that elevated 2HG causes changes in gene function that are independent of intrinsic DNA sequence (epigenetic regulation). This causes a block in the normal process of cellular differentiation from a precursor cell into different mature cell types, and instead leads to cancerous transformation

  • Source

Updated by MV

IDH1, Advanced Cholangiocarcinoma, ClarIDHy, Agios, AGIO

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon